Tactile Systems Technology Inc Dossier - Source-backed chat

Tactile Systems Technology Inc

TCMDNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.89

Intrinsic Value $41.42median of 6 methods · middle span $20-$183based on filings through 30 Jun 2026

Market Price $21.71Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 91% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+91%)

Data confidence Sign in to view data confidence

Market Cap $491.8M

Enterprise Value $421.9M

Shares Outstanding 22.8M diluted

Moat Rating Narrow

Next Earnings Date2 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Tactile Systems Technology (TCMD) is a leading medical technology provider specializing in at-home therapies for chronic conditions like lymphedema and chronic pulmonary secretion. The company's investment thesis is anchored on robust top-line momentum (23% YoY revenue growth in Q1 2026), significant gross margin expansion to 76.5%, and strong operating leverage. With a fully resourced sales force, the strategic acquisition of LymphaTech to enhance diagnostic capabilities, and the launch of the Nimbl platform to capture early-stage patients, TCMD is well-positioned to expand its market share. Despite regulatory headwinds such as Medicare prior authorization, TCMD's direct-to-provider model and technological agility provide a highly defensive growth profile at an attractive valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$36.00

Mean target$39.50

High · most bullish analyst$42.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$31.0020%

Medicare prior authorization requirements cause persistent bottlenecks in order processing, slowing down revenue conversion. Increased competition from wearable, non-pneumatic alternatives like Koya's Dayspring erodes market share in the lymphedema segment, compressing gross margins and limiting FY 2026 revenue growth to under 5%.

Base CaseCentral scenario

$39.5050%

Matches the consensus mean

TCMD successfully executes its commercial strategy, achieving FY 2026 revenue of $360M to $368M (9% to 12% growth) and Adjusted EBITDA of $49M to $51M. Sales rep productivity continues to improve, and the LymphaTech integration proceeds smoothly, maintaining TCMD's dominant position in the lymphedema market.

Bull CaseUpside scenario

$42.0030%

Accelerated adoption of the Flexitouch Plus and AffloVest systems, combined with rapid market penetration of the newly launched Nimbl platform, drives revenue growth to the high end of guidance (12%+). Operational efficiencies from the AI-enabled order management platform completely offset Medicare prior authorization friction, leading to EBITDA margins exceeding 15%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong top-line momentum with 23% YoY revenue growth in Q1 2026, driven by broad-based execution across lymphedema and airway clearance segments.
Industry-leading gross margins of 76.5%, providing substantial operating leverage as the business scales.
Strategic product expansion with the FDA 510(k) clearance of the next-generation AffloVest and the commercial rollout of the Nimbl platform.
Active capital allocation including a newly announced share repurchase program to support shareholder value.

Key Investment Risks

Regulatory and reimbursement headwinds, specifically the implementation of Medicare prior authorization requirements for PCDs.
Competitive threats from disruptive, non-pneumatic wearable technologies (e.g., Koya Medical's Dayspring).
Execution risks associated with the integration and commercialization of the newly acquired LymphaTech diagnostic technology.

Thesis Invalidation Triggers

A material decline in gross margins below 72% due to pricing pressure or unfavorable product mix.
Failure of the Nimbl platform to defend market share against wearable competitors, resulting in flat or negative lymphedema segment growth.
Severe operational bottlenecks from Medicare prior authorization leading to a downward revision of FY 2026 revenue guidance below $350 million.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.